# Adam Oskowitz

> Adam Oskowitz is a vascular surgeon, scientist, UCSF faculty member, and co-founder and co-CEO of Doctronic. After training at Dartmouth, Tulane, and UCLA, he built a clinical and research career around complex vascular care and regenerative science, then partnered with technologist Matt Pavelle to build an AI-native care company. Doctronic's rise - including a $40 million Series B in March 2026 and a Utah regulatory program for autonomous prescription renewals - has placed Oskowitz at the center of the debate over how software should participate in clinical decisions.

- **Role:** Co-Founder and Co-CEO at Doctronic; Associate Professor of Surgery at UCSF; Chief of Vascular Surgery at Zuckerberg San Francisco General
- **Organizations:** Doctronic, University of California, San Francisco, Zuckerberg San Francisco General Hospital, UCLA Medical Center, Tulane University, Dartmouth College
- **Education:** Master of Public Health, Dartmouth College, MD and PhD, Tulane University, General Surgery Residency; Chief Resident, UCLA Medical Center, Vascular Surgery Fellowship, UCLA Medical Center
- **Known for:** Co-founded Doctronic with Matt Pavelle and serves as co-CEO., Appointed Chief of Vascular Surgery at Zuckerberg San Francisco General., Serves as an Associate Professor of Surgery at the University of California, San Francisco.

## Career timeline

- **2009** — Completed medical and doctoral training at Tulane University.
- **2010-2014** — Completed general surgery training at UCLA Medical Center and served as chief resident.
- **2014-2016** — Completed a vascular surgery fellowship at UCLA.
- **2016** — Joined UCSF's Division of Vascular and Endovascular Surgery.
- **2018** — Received American Board of Surgery certification in vascular surgery.
- **2020** — Received a $400,000 NIH R21 Trailblazer Award for high-risk, high-impact vascular research.
- **2023** — Received UCSF research support for a project on the dynamic role of T-cells in aortic aneurysms.
- **2024** — Co-founded Doctronic with Matt Pavelle.
- **2025** — Appointed Chief of Vascular Surgery at Zuckerberg San Francisco General, according to the hospital's 2024-2025 annual report.
- **2025-09** — Doctronic announced a $20 million Series A led by Lightspeed.
- **2026-03** — Doctronic announced a $40 million Series B, bringing total funding above $65 million.

## Achievements

- Co-founded Doctronic with Matt Pavelle and serves as co-CEO.
- Appointed Chief of Vascular Surgery at Zuckerberg San Francisco General.
- Serves as an Associate Professor of Surgery at the University of California, San Francisco.
- Received a $400,000 NIH R21 Trailblazer Award in 2020.
- Board-certified by the American Board of Surgery in general surgery and vascular surgery.
- Co-authored research spanning regenerative medicine, vascular surgery, and spatial transcriptomics.
- Helped Doctronic raise more than $65 million across three funding rounds by March 2026.

## Latest updates

- **2026-03** — Doctronic announced a $40 million Series B co-led by Abstract and Lightspeed, taking total funding above $65 million.
- **2026-03** — Oskowitz discussed Doctronic's expansion plans and Utah program with Yahoo Finance and appeared on TBPN.
- **2026-01** — Doctronic began operating an autonomous prescription-renewal program through Utah's AI Learning Lab regulatory sandbox.
- **2025-11** — Oskowitz appeared as a corresponding author on a preprint mapping cellular organization in human aortic aneurysm tissue.
- **2025-09** — Doctronic announced a $20 million Series A led by Lightspeed.

## Links

- Website: https://doctronic.ai
- LinkedIn: https://www.linkedin.com/in/adamoskowitz

---

Profile page: https://yespress.io/adam-oskowitz
Published by YesPress — https://yespress.io
Last updated: 2026-08-17